Related Experiment Video
Updated: Sep 27, 2025

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
Published on: February 27, 2019
Advances in oral peptide drug nanoparticles for diabetes mellitus treatment
Yan Li1, Wen Zhang1, Ruichen Zhao2,3
1School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, 100083, PR China.
Abstract:
Peptide drugs play an important role in diabetes mellitus treatment. Oral administration of peptide drugs is a promising strategy for diabetes mellitus because of its convenience and high patient compliance compared to parenteral administration routes. However, there are a series of formidable unfavorable conditions present in the gastrointestinal (GI) tract after oral administration, which result in the low oral bioavailability of these peptide drugs. To overcome these challenges, various nanoparticles (NPs) have been developed to improve the oral absorption of peptide drugs due to their unique in vivo properties and high design flexibility. This review discusses the unfavorable conditions present in the GI tract and provides the corresponding strategies to overcome these challenges. The review provides a comprehensive overview on the NPs that have been constructed for oral peptide drug delivery in diabetes mellitus treatment. Finally, we will discuss the rational application and give some suggestions that can be utilized for the development of oral peptide drug NPs. Our aim is to provide a systemic and comprehensive review of oral peptide drug NPs that can overcome the challenges in GI tract for efficient treatment of diabetes mellitus.
More Related Videos
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
05:06Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy
Published on: November 10, 2023
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Glinides
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...